why choose us

Clinical Trials Search

Showing 14,860 of 132,656 result(s)
EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

Status: COMPLETED

Condition: Lipid Disorder

Interventions: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)

Date: 2023-02-15

Adaptation and Evaluation of Bright Horizons

Status: NOT_YET_RECRUITING

Condition: Alcohol Abuse

Interventions: Bright Horizons is a brief substance use intervention delivered by Research Program Assistants.

Date: 2023-02-15

The Brain Metabolism of Unpredictable Signals

Status: NOT_YET_RECRUITING

Condition: Healthy

Interventions: Subjects will complete four task conditions in each scan session: (1) Visual Unpredictable, (2) Visual Predictable, (3) Auditory Unpredictable, and (4

Date: 2023-02-15

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Status: Completed

Condition: Respiratory Syncytial Virus

Interventions: Sterile liquid for injection

Date: 2023-02-15

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Status: COMPLETED

Condition: Diabetes Mellitus

Interventions: DA-2811 Group: DA-2811 + Forxiga placebo

Date: 2023-02-15

Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

Status: COMPLETED

Condition: GM2 Gangliosidosis
Niemann-Pick Disease, Type C

Interventions: DRUG: AZ-3102 (Dose 1) - Pharmaceutical form: capsule

Route of administration: oral
DRUG: Placebo - Pharmaceutical form: capsule

Date: 2023-02-15

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Status: COMPLETED

Condition: Locally Advanced Biliary Tract Cancer
Metastatic Biliary Tract Cancer

Interventions: DRUG: Camrelizumab and Apatinib Plus GP - Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.

Camrel

Date: 2023-02-15

Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?

Status: COMPLETED

Condition: Chemotherapy-induced Peripheral Neuropathy

Interventions:

Date: 2023-02-15

Exogenous Ketone Ester in Women with Polycystic Ovary Syndrome.

Status: COMPLETED

Condition: PCOS

Interventions: 60 ml (30 g) of 3-OHB

Date: 2023-02-15

Time Restricted Eating for Weight Loss Maintenance

Status: COMPLETED

Condition: Obesity

Interventions: TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours.

Date: 2023-02-15